Profile: Arena Pharmaceuticals Inc (ARNA.A)
Arena Pharmaceuticals, Inc., incorporated on April 14, 1997, is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Company`s drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development, which include APD811, Temanogrel, APD334 and APD371.
BELVIQ is an approved drug used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kilograms/m2 or greater (obese), or 27 kilograms/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition, such as hypertension, dyslipidemia, type 2 diabetes.
APD811, an orally available agonist of the prostacyclin (IP) receptor, is an investigational drug candidate internally discovered and developed for the treatment of vasospastic diseases, such as pulmonary arterial hypertension. APD811 has completed single- and multiple-ascending dose Phase I trials in healthy volunteers.
Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases. Temanogrel has completed single- and multiple-ascending dose Phase I trials in healthy volunteers.
APD334, an orally available agonist of the sphingosine 1-phosphate subtype 1 (S1P1) receptor, is an internally discovered investigational drug candidate indicated for the treatment of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis. S1P1 receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage. APD334 has been identified as a potent and selective small molecule S1P1 receptor agonist that reduces the severity of disease in preclinical autoimmune disease models. The Company has completed a randomized, double-blind and placebo-controlled Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334.
APD371, an orally available agonist of the cannabinoid 2 (CB2) receptor, is an internally discovered investigational drug candidate intended for the treatment of pain. The Company has identified several potent, CB2-selective compounds that are intended to retain the analgesic activity of the CB receptor agonists while avoiding the limiting psychotropic side effects. Preclinical efficacy with these CB2 receptor agonists has been demonstrated in animal models of pain. The Company has initiated a randomized, double-blind and placebo-controlled Phase I trial to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD371 in healthy adult volunteers.
The Company competes with Hoffmann-La Roche Inc., Roche Group, GlaxoSmithKline and VIVUS Inc.
Arena Pharmaceuticals Inc
6154 Nancy Ridge Dr
SAN DIEGO CA 92121-3223